Stories
Sagility Shares Can Surge Up To 40 Percent Says Nuvama With Buy Rating

C
CNBC TV18•08-10-2026, 12:32
Sagility Shares Can Surge Up To 40 Percent Says Nuvama With Buy Rating
- •Brokerage firm Nuvama initiated coverage on Sagility Ltd. with a buy rating and a target price of ₹60, indicating a 39.2 percent upside from its previous close.
- •Nuvama highlights that healthcare business process management is entering an AI-led transformation era, with US healthcare outsourcing expected to grow significantly.
- •The brokerage estimates Sagility's US Dollar revenue to grow at a 13 percent CAGR and adjusted EPS at a 19 percent CAGR over the financial years 2026 to 2029.
- •Sagility is expected to become a net cash company by the current financial year due to strong free cash flow generation and debt repayment.
- •Sagility Group CEO and MD Ramesh Gopalan previously reaffirmed the company's full-year guidance of low double-digit organic growth for FY27.
Key Questions Answered
Brokerage firm Nuvama has initiated coverage on Sagility Ltd. with a "buy" rating and set a target price of ₹60, which implies an upside of approximately 39.2% from its previous closing price.
According to Nuvama, US healthcare operations spend is anticipated to increase from $201 billion in calendar year 2023 to reach up to $259 billion by calendar year 2028.
Nuvama projects that Sagility's revenue in US Dollar terms will grow at a Compounded Annual Growth Rate of 13% over the financial years 2026 to 2029, while its adjusted EPS could achieve a 19% CAGR over the same period.





